Cortexyme Inc. (CRTX)
NASDAQ: CRTX
· Real-Time Price · USD
1.95
0.05 (2.63%)
At close: Aug 01, 2022, 6:00 AM
Cortexyme Revenue Breakdown
| Period Ending | Dec 31, 2012 |
|---|---|
| Allerx Dose Pack Products Revenue | -1.41M |
| Allerx Dose Pack Products Revenue Growth | n/a |
| Anti Infective Revenue | 3.37M |
| Anti Infective Revenue Growth | n/a |
| Cardene Revenue | 24.81M |
| Cardene Revenue Growth | n/a |
| Curosurf Revenue | 34.97M |
| Curosurf Revenue Growth | n/a |
| Other Products Revenue | 781K |
| Other Products Revenue Growth | n/a |
| Zyflo Revenue | 53.55M |
| Zyflo Revenue Growth | n/a |
Operating Expense Breakdown
| Period Ending | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selling, General, and Administrative Revenue | 9.06M | 9.11M | 29.52M | 7.64M | 7.06M | 6.49M | 5M | 4.93M | 4.18M | 3.48M | 2.92M | 2.32M | 2.47M | 1.25M | 746K | 584K | 357K | 347K |
| Selling, General, and Administrative Revenue Growth | -0.52% | -69.16% | +286.48% | +8.14% | +8.86% | +29.91% | +1.34% | +17.78% | +20.33% | +19.03% | +26.17% | -6.08% | +97.28% | +67.56% | +27.74% | +63.59% | +2.88% | n/a |
| Research and Development Revenue | 7.2M | 12.76M | 60.8M | 14.04M | 14.72M | 16.82M | 15.86M | 16.98M | 14.09M | 14.38M | 10.03M | 8.25M | 7.11M | 4.83M | 3.1M | 2.29M | 2.29M | 2.41M |
| Research and Development Revenue Growth | -43.57% | -79.02% | +333.07% | -4.63% | -12.51% | +6.10% | -6.63% | +20.57% | -2.04% | +43.41% | +21.50% | +16.09% | +47.34% | +55.85% | +35.20% | +0.17% | -5.26% | n/a |